Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8889640 | 0.86 | HRH4 (0.55) | FLT3HRH4MAP2K1 | |
| SCHEMBL16600387 | 0.85 | FLT3 (0.74) | FLT3HRH4HRH3MEN1KMT2A | |
| SCHEMBL378196 | 0.84 | SMAD3 (0.66) | FLT3HRH4HRH3MEN1KMT2A | |
| SCHEMBL6919619 | 0.82 | FLT3 (0.57) | FLT3HRH4HRH3MEN1KMT2A | |
| SCHEMBL2729921 | 0.82 | FLT3 (0.61) | FLT3HRH4HRH3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6919627 | 0.82 | SMAD3 (0.64) | FLT3HRH4HRH3MEN1KMT2A | |
| SCHEMBL1651087 | 0.80 | MMP2 (0.66) | FLT3HRH4HRH3MEN1KMT2A | |
| SCHEMBL3608666 | 0.80 | HRH4 (0.56) | FLT3HRH4HDAC2ABL1PDGFRB | |
| SCHEMBL3282981 | 0.80 | FLT3 (0.73) | FLT3HRH4ABL1PDGFRBKIT | |
| SCHEMBL12086506 | 0.79 | HRH4 (0.55) | FLT3HRH4HRH3ABL1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171040-A | Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof | 常州大学 | 2020-05-19 | — | — | CN | claimed |
| EP-4387965-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CHEMOCENTRYX, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-118019735-A | Arylsulfonyl compounds as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023023534-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| CN-112521369-A | Compounds and compositions for inhibition of FASN | 福马治疗股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-1933830-A | Indole derivatives and their use as kinase inhibitors, in particular IKK2 inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1703905-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006077367-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
| US-20060074076-A1 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006023590-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006010008-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005067923-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-1250324-A1 | BIARYL COMPOUNDS, THEIR PREPARATION AND THEIR USE IN THERAPY | RiboTargets Limited (GB) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001055111-A1 | BIARYL COMPOUNDS, THEIR PREPARATION AND THEIR USE IN THERAPY | RIBOTARGETS LIMITED (GB) | 2001-08-02 | — | — | WO | disclosed |
| WO-1997008167-A1 | 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CCR6, CCR1, CCR3 | FLT3 1073/4885HRH4 509/4885HRH3 586/4885 |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CCR6, CCR1, CCR3 | FLT3 1073/4885HRH4 509/4885HRH3 586/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FLT3 4065/4885HRH4 4003/4885HRH3 4167/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FLT3 4088/4885HRH4 4040/4885HRH3 4245/4885 |
| US-20060074076-A1 | Heterocyclic derivatives for modulation of calcium channels | CACNA1D, ORAI1, CACNA1C | FLT3 4518/4885HRH4 576/4885HRH3 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.